Article · AI translation
IT Home reported on October 28 that NeuroXess, a Chinese brain-computer interface company, announced this morning (the 28th) that it had completed a RMB 700 million Series B financing round. The round was jointly led by SDIC Jul i, Shenzhen Capital Group and Qinzhi Capital, with participation from well-known institutions including Zhongxin Juyuan, Huangpu Investment, Cornerstone Capital, IDG Capital, Xichen Capital, Junxi Capital, Huafu Securities, Huasai Zhihui, Zhongwei Capital and Jiangxi Financial Holding. Shanda, Zhongping Capital and other institutions continued their support.
The funds raised in this round will reportedly be used for multicenter clinical trials and registration approval of the “three-all” brain-computer interface system (IT Home note: fully implanted, fully wireless and fully functional), construction of a superfactory for mass production, development of next-generation products, and exploration of the integration of BCI and AI.
This financing round will focus on four areas: multicenter registration clinical trials and registration approval for the “three-all” system, construction of a superfactory for mass production, development of next-generation products, and continued exploration of BCI and AI integration.
Next-generation product development will focus on continued iteration and performance optimization of language brain-computer interfaces, while accelerating research and development of visual brain-computer interfaces to further expand the range of conditions the technology can address;
Work on BCI+AI integration will involve continued investment in using intentions to invoke AI, connect to tools and control the environment, among other areas. The company will explore BCI+AI models of the real physical world, continuously collect brain activity data in real-world settings, and expand the possibilities for next-generation human-computer interaction.
NeuroXess aims to bring its products into the medical market at scale within two years so that the cutting-edge technology can benefit more patients.
NeuroXess said another notable feature of this financing round was the concentrated participation of leading investors from different sectors. The entry of Zhongxin Juyuan, a leading industrial investor deeply involved in the semiconductor industry chain; Cornerstone Capital, a well-known private equity firm that has long focused on hard technology throughout its life cycle; and IDG Capital, a top-tier general venture capital firm, together forms a diverse group of top-tier investors. Continued support from existing shareholders including Shanda and Zhongping Capital further confirms the capital market’s long-term confidence in NeuroXess.